|
DUBAI, UAE, April 10, 2026 /PRNewswire/ -- Mantle, the high-performance distribution layer for real-world assets (RWAs), connecting traditional finance and on-chain liquidity, and Bybit, the world's leading global cryptocurrency exchange, today announced the live integration of xStocks on Mantle. In collaboration with BackedFi, xStocks, and Flowdesk, Mantle becomes one of the first Ethereum Layer 2 networks to bring tokenized equities to on-chain liquidity, enabling users to trade the world's top tokenized equities around the clock, globally, on-chain via Fluxion, Mantle's native decentralised exchange.
The integration marks a significant milestone in Mantle's mission to serve as the go-to real-world asset (RWA) chain, bridging the gap between traditional finance and on-chain liquidity together with decentralised finance through its institutional-grade infrastructure, composability, and unparalleled distribution reach.
Bringing Tokenized Equities to On-Chain Liquidity
xStocks are tokenized tracker certificates that provide on-chain exposure to leading public equities. They are fully collateralized by the underlying securities and compliant under the Swiss DLT Act.
By integrating xStocks on Mantle, tradable via Fluxion, one of Mantle's native DEX, Fluxion's hybrid Automated Market Maker (AMM) and Request for Quote (RFQ) infrastructure ensures that users can trade tokenized assets with institutional-grade precision and minimal slippage.
Users gain seamless access to some of the world's most sought-after tokenized equities, including TSLAx, NVDAx, AAPLx, METAx, GOOGLx, MSTRx, HOODx, SPYx, QQQx, and CRCLx tradable any day of the week, globally accessible where permitted.
Unlike traditional equity markets bound by opening hours and market schedules, xStocks on Mantle enables users to gain exposure to leading global equities any day of the week, responding to market developments as they happen rather than waiting for exchanges to open.
Why Mantle: The Distribution Layer Advantage
Mantle's integration of xStocks is underpinned by three core pillars that set the chain apart as the right home for RWAs to move from.
- Institutional-Grade Infrastructure: Mantle Chain provides the compliance-friendly, high-performance blockchain infrastructure required for tokenized asset distribution at scale.
- Composability: xStocks on Mantle is fully composable with a 200+ partner ecosystem, enabling builders and protocols to design capital-efficient strategies around tokenized equities with deep on-chain liquidity.
- Unparalleled Reach with Bybit: As one of the few chains with direct deposit and withdrawal support for xStocks exclusively through Bybit, Mantle provides an unmatched distribution gateway for retail and institutional capital, seamlessly connecting centralised and on-chain markets.
"Real-world assets have long needed a distribution layer with the reach and rails that institutional adoption demands," said Emily Bao, Key Advisor at Mantle and Spot Executive at Bybit. "The integration of xStocks on Mantle demonstrates exactly what becomes possible when the right teams unite around the right infrastructure to meet the right assets. Mantle was always the home for RWAs, not just to house them, but to distribute them at scale. This is what the distribution layer was built for."
The Future of RWA is on Mantle
The xStocks integration on Mantle represents the first phase of a broader roadmap designed to deepen liquidity, improve execution, and reward early participants within the Mantle ecosystem. Subsequent phases together with BackedFi, will introduce xChange (Atomic RFQ) support and the xPoints loyalty programme, further expanding the utility and accessibility of tokenized equities through xStocks on Mantle.
"Tokenized equities have the potential to reshape how people access public markets by making them more global, more programmable, and more connected to on-chain capital," said Val Gui, GM of xStocks. "xStocks is built to help reimagine that access on-chain, and our expansion to Mantle is part of bringing tokenized equities into more global, crypto-native markets."
Through this collaboration, Mantle continues to cement its position as the premier distribution layer for RWAs, combining institutional-grade security with the scalability of a next-generation Layer 2.
About Mantle
Mantle positions itself as the premier distribution layer and gateway for institutions and TradFi to connect with on-chain liquidity and access real-world assets, powering how real-world finance flows. With over $4B+ in community-owned assets, Mantle combines credibility, liquidity and scalability with institutional-grade infrastructure to support large-scale adoption. The ecosystem is anchored by $MNT within Bybit, and built out through core ecosystem projects like mETH, fBTC, MI4 and more. This is complemented by Mantle Network's partnerships with leading issuers and protocols such as Ethena USDe, Ondo USDY, and OP-Succinct. For more information visit mantle.xyz.
For more social updates, please follow: Mantle Official X & Mantle Community Channel
For media enquiries, please contact: contact@mantle.xyz
About Bybit
Bybit is the world's second-largest cryptocurrency exchange by trading volume, serving a global community of over 80 million users. Founded in 2018, Bybit is redefining openness in the decentralized world by creating a simpler, open, and equal ecosystem for everyone. With a strong focus on Web3, Bybit partners strategically with leading blockchain protocols to provide robust infrastructure and drive on-chain innovation. Renowned for its secure custody, diverse marketplaces, intuitive user experience, and advanced blockchain tools, Bybit bridges the gap between TradFi and DeFi, empowering builders, creators, and enthusiasts to unlock the full potential of Web3. Discover the future of decentralized finance at Bybit.com.
For more details about Bybit, please visit Bybit Press
For media inquiries, please contact: media@bybit.com
About Backed
Founded in 2021, Backed is the leading issuer of compliant tokenized equities and ETFs, including the innovative xStocks line of products. Backed's products are freely transferable ERC-20 and SPL tokens compatible with Ethereum and Solana-based platforms. For more information, please visit https://backed.fi/
DUBAI, UAE, April 10, 2026 /PRNewswire/ -- Mantle, the high-performance distribution layer for real-world assets (RWAs), connecting traditional finance and on-chain liquidity, and Bybit, the world's leading global cryptocurrency exchange, today announced the live integration of xStocks on Mantle. In collaboration with BackedFi, xStocks, and Flowdesk, Mantle becomes one of the first Ethereum Layer 2 networks to bring tokenized equities to on-chain liquidity, enabling users to trade the world's top tokenized equities around the clock, globally, on-chain via Fluxion, Mantle's native decentralised exchange.
The integration marks a significant milestone in Mantle's mission to serve as the go-to real-world asset (RWA) chain, bridging the gap between traditional finance and on-chain liquidity together with decentralised finance through its institutional-grade infrastructure, composability, and unparalleled distribution reach.
Bringing Tokenized Equities to On-Chain Liquidity
xStocks are tokenized tracker certificates that provide on-chain exposure to leading public equities. They are fully collateralized by the underlying securities and compliant under the Swiss DLT Act.
By integrating xStocks on Mantle, tradable via Fluxion, one of Mantle's native DEX, Fluxion's hybrid Automated Market Maker (AMM) and Request for Quote (RFQ) infrastructure ensures that users can trade tokenized assets with institutional-grade precision and minimal slippage.
Users gain seamless access to some of the world's most sought-after tokenized equities, including TSLAx, NVDAx, AAPLx, METAx, GOOGLx, MSTRx, HOODx, SPYx, QQQx, and CRCLx tradable any day of the week, globally accessible where permitted.
Unlike traditional equity markets bound by opening hours and market schedules, xStocks on Mantle enables users to gain exposure to leading global equities any day of the week, responding to market developments as they happen rather than waiting for exchanges to open.
Why Mantle: The Distribution Layer Advantage
Mantle's integration of xStocks is underpinned by three core pillars that set the chain apart as the right home for RWAs to move from.
- Institutional-Grade Infrastructure: Mantle Chain provides the compliance-friendly, high-performance blockchain infrastructure required for tokenized asset distribution at scale.
- Composability: xStocks on Mantle is fully composable with a 200+ partner ecosystem, enabling builders and protocols to design capital-efficient strategies around tokenized equities with deep on-chain liquidity.
- Unparalleled Reach with Bybit: As one of the few chains with direct deposit and withdrawal support for xStocks exclusively through Bybit, Mantle provides an unmatched distribution gateway for retail and institutional capital, seamlessly connecting centralised and on-chain markets.
"Real-world assets have long needed a distribution layer with the reach and rails that institutional adoption demands," said Emily Bao, Key Advisor at Mantle and Spot Executive at Bybit. "The integration of xStocks on Mantle demonstrates exactly what becomes possible when the right teams unite around the right infrastructure to meet the right assets. Mantle was always the home for RWAs, not just to house them, but to distribute them at scale. This is what the distribution layer was built for."
The Future of RWA is on Mantle
The xStocks integration on Mantle represents the first phase of a broader roadmap designed to deepen liquidity, improve execution, and reward early participants within the Mantle ecosystem. Subsequent phases together with BackedFi, will introduce xChange (Atomic RFQ) support and the xPoints loyalty programme, further expanding the utility and accessibility of tokenized equities through xStocks on Mantle.
"Tokenized equities have the potential to reshape how people access public markets by making them more global, more programmable, and more connected to on-chain capital," said Val Gui, GM of xStocks. "xStocks is built to help reimagine that access on-chain, and our expansion to Mantle is part of bringing tokenized equities into more global, crypto-native markets."
Through this collaboration, Mantle continues to cement its position as the premier distribution layer for RWAs, combining institutional-grade security with the scalability of a next-generation Layer 2.
About Mantle
Mantle positions itself as the premier distribution layer and gateway for institutions and TradFi to connect with on-chain liquidity and access real-world assets, powering how real-world finance flows. With over $4B+ in community-owned assets, Mantle combines credibility, liquidity and scalability with institutional-grade infrastructure to support large-scale adoption. The ecosystem is anchored by $MNT within Bybit, and built out through core ecosystem projects like mETH, fBTC, MI4 and more. This is complemented by Mantle Network's partnerships with leading issuers and protocols such as Ethena USDe, Ondo USDY, and OP-Succinct. For more information visit mantle.xyz.
For more social updates, please follow: Mantle Official X & Mantle Community Channel
For media enquiries, please contact: contact@mantle.xyz
About Bybit
Bybit is the world's second-largest cryptocurrency exchange by trading volume, serving a global community of over 80 million users. Founded in 2018, Bybit is redefining openness in the decentralized world by creating a simpler, open, and equal ecosystem for everyone. With a strong focus on Web3, Bybit partners strategically with leading blockchain protocols to provide robust infrastructure and drive on-chain innovation. Renowned for its secure custody, diverse marketplaces, intuitive user experience, and advanced blockchain tools, Bybit bridges the gap between TradFi and DeFi, empowering builders, creators, and enthusiasts to unlock the full potential of Web3. Discover the future of decentralized finance at Bybit.com.
For more details about Bybit, please visit Bybit Press
For media inquiries, please contact: media@bybit.com
About Backed
Founded in 2021, Backed is the leading issuer of compliant tokenized equities and ETFs, including the innovative xStocks line of products. Backed's products are freely transferable ERC-20 and SPL tokens compatible with Ethereum and Solana-based platforms. For more information, please visit https://backed.fi/
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
Mantle Becomes One of the First Ethereum L2s to Bring Tokenized Equities to On-Chain Liquidity with xStocks and Bybit
|
CHENGDU, China, May 30, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company", 6990.HK) announced that at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, USA, results from the pivotal Phase II study of the Company's next-generation selective RET inhibitor, lunbotinib fumarate (A400/EP0031, 宁泰莱®[1]), in advanced rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC) were presented as an oral report by Professor Qing Zhou from Guangdong Provincial People's Hospital (Abstract #8505, Lung Cancer—Metastatic Non-Small Cell). Based on these results, a New Drug Application (NDA) for lunbotinib fumarate for the treatment of adult patients with locally advanced or metastatic RET fusion-positive NSCLC has been accepted by the National Medical Products Administration (NMPA) of China.
The study enrolled 71 patients who had previously received platinum-based chemotherapy and immunotherapy (pre-treated patients) and 92 patients who had not received prior systemic therapy (treatment-naïve patients). As of the data cutoff date of October 29, 2025, the median follow-up was 22.6 months and 20.7 months, respectively.
The confirmed objective response rate (ORR) assessed by Independent Review Committee (IRC) was 81.3% (95% CI: 71.8–88.7) in treatment-naïve patients and 87.1% (95% CI: 77.0–93.9) in pre-treated patients.
In treatment-naïve patients, median duration of response (mDOR) and median progression-free survival (mPFS) were not reached. In pre-treated patients, mDOR was 25.7 months, and mPFS was 27.5 months.
Among 40 patients with central nervous system (CNS) metastases at baseline (assessed by IRC per response assessment in neuro-oncology brain metastases (RANO-BM) criteria), the intracranial complete response (CR) rate was 30%, and the disease control rate (DCR) was 92.5% (95% CI: 79.6–98.4).
Lunbotinib fumarate was well tolerated, with treatment-related adverse events (TRAEs) being predominantly Grade 1–2. The rate of permanent discontinuation due to TRAEs was 1.2%, and no treatment-related deaths were reported.
The study shows that lunbotinib fumarate demonstrated robust and durable clinical activity in RET fusion-positive NSCLC, regardless of line of therapy, in a largely poor-prognostic patient population. Favorable CNS efficacy was observed in patients with measurable baseline CNS metastases. The safety profile was manageable, with no unexpected safety signals.
Professor Qing Zhou, principal investigator from Guangdong Provincial People's Hospital, said: "From the first presentation of Phase I data at ASCO 2023 to today's pivotal Phase II results, we have witnessed the progression of lunbotinib fumarate from early exploration to a confirmatory study. These data show that lunbotinib fumarate delivers robust and durable responses in both treatment-naïve and pre-treated patients with RET fusion-positive NSCLC, with particularly remarkable intracranial efficacy in patients with CNS metastases at baseline. As a next-generation selective RET inhibitor, it will offer an important new treatment option for patients."
| [1] Trade name to be approved by NMPA. |
|
About lunbotinib fumarate (A400/EP0031, 宁泰莱®)
Lunbotinib fumarate is a novel, next-generation selective RET inhibitor for NSCLC, medullary thyroid cancer (MTC) and other solid tumors with a high prevalence of RET alterations. The NDA of lunbotinib fumarate has been accepted for review by the NMPA of China for the treatment of adult patients with RET-fusion positive locally advanced or metastatic NSCLC. The Company is also conducting a Phase Ib/II clinical study in China for the treatment of RET-positive solid tumors.
In March 2021, the Company granted Ellipses Pharma Limited, a U.K.-based international oncology drug development company, an exclusive license to develop, manufacture and commercialize this agent outside Greater China and certain Asian countries. In April 2024, lunbotinib fumarate was cleared by the Food and Drug Administration (FDA) to progress into a Phase II clinical trial (NCT05443126) which is currently recruiting in the United States, United Kingdom, Europe and United Arab Emirates, where it is being evaluated as a monotherapy and in combination with chemotherapy in RET fusion positive advanced NSCLC.
About Kelun-Biotech
Kelun-Biotech (6990.HK) is a holding subsidiary of Kelun Pharmaceutical, which focuses on the R&D, manufacturing, commercialization and global collaboration of innovative biological drugs and small molecule drugs. Kelun-Biotech focuses on major disease areas such as solid tumors, autoimmune, and metabolic diseases, and in establishing a globalized drug development and industrialization platform to address the unmet medical needs in China and the rest of world. Kelun-Biotech is committed to becoming a leading global enterprise in the field of innovative drugs. At present, Kelun-Biotech has more than 30 ongoing key innovative drug projects, of which 4 projects with 8 indications have been approved for marketing, 1 project is in the NDA stage and more than 10 projects are in the clinical stage. Kelun-Biotech has established one of the world's leading proprietary ADC and novel DC platforms, OptiDC™, and has 2 ADC projects with 5 indications approved for marketing, and multiple ADC and novel DC assets in clinical or preclinical research stage. For more information, please visit https://en.kelun-biotech.com/.
CHENGDU, China, May 30, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company", 6990.HK) announced that at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, USA, results from the pivotal Phase II study of the Company's next-generation selective RET inhibitor, lunbotinib fumarate (A400/EP0031, 宁泰莱®[1]), in advanced rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC) were presented as an oral report by Professor Qing Zhou from Guangdong Provincial People's Hospital (Abstract #8505, Lung Cancer—Metastatic Non-Small Cell). Based on these results, a New Drug Application (NDA) for lunbotinib fumarate for the treatment of adult patients with locally advanced or metastatic RET fusion-positive NSCLC has been accepted by the National Medical Products Administration (NMPA) of China.
The study enrolled 71 patients who had previously received platinum-based chemotherapy and immunotherapy (pre-treated patients) and 92 patients who had not received prior systemic therapy (treatment-naïve patients). As of the data cutoff date of October 29, 2025, the median follow-up was 22.6 months and 20.7 months, respectively.
The confirmed objective response rate (ORR) assessed by Independent Review Committee (IRC) was 81.3% (95% CI: 71.8–88.7) in treatment-naïve patients and 87.1% (95% CI: 77.0–93.9) in pre-treated patients.
In treatment-naïve patients, median duration of response (mDOR) and median progression-free survival (mPFS) were not reached. In pre-treated patients, mDOR was 25.7 months, and mPFS was 27.5 months.
Among 40 patients with central nervous system (CNS) metastases at baseline (assessed by IRC per response assessment in neuro-oncology brain metastases (RANO-BM) criteria), the intracranial complete response (CR) rate was 30%, and the disease control rate (DCR) was 92.5% (95% CI: 79.6–98.4).
Lunbotinib fumarate was well tolerated, with treatment-related adverse events (TRAEs) being predominantly Grade 1–2. The rate of permanent discontinuation due to TRAEs was 1.2%, and no treatment-related deaths were reported.
The study shows that lunbotinib fumarate demonstrated robust and durable clinical activity in RET fusion-positive NSCLC, regardless of line of therapy, in a largely poor-prognostic patient population. Favorable CNS efficacy was observed in patients with measurable baseline CNS metastases. The safety profile was manageable, with no unexpected safety signals.
Professor Qing Zhou, principal investigator from Guangdong Provincial People's Hospital, said: "From the first presentation of Phase I data at ASCO 2023 to today's pivotal Phase II results, we have witnessed the progression of lunbotinib fumarate from early exploration to a confirmatory study. These data show that lunbotinib fumarate delivers robust and durable responses in both treatment-naïve and pre-treated patients with RET fusion-positive NSCLC, with particularly remarkable intracranial efficacy in patients with CNS metastases at baseline. As a next-generation selective RET inhibitor, it will offer an important new treatment option for patients."
[1] Trade name to be approved by NMPA.
About lunbotinib fumarate (A400/EP0031, 宁泰莱®)
Lunbotinib fumarate is a novel, next-generation selective RET inhibitor for NSCLC, medullary thyroid cancer (MTC) and other solid tumors with a high prevalence of RET alterations. The NDA of lunbotinib fumarate has been accepted for review by the NMPA of China for the treatment of adult patients with RET-fusion positive locally advanced or metastatic NSCLC. The Company is also conducting a Phase Ib/II clinical study in China for the treatment of RET-positive solid tumors.
In March 2021, the Company granted Ellipses Pharma Limited, a U.K.-based international oncology drug development company, an exclusive license to develop, manufacture and commercialize this agent outside Greater China and certain Asian countries. In April 2024, lunbotinib fumarate was cleared by the Food and Drug Administration (FDA) to progress into a Phase II clinical trial (NCT05443126) which is currently recruiting in the United States, United Kingdom, Europe and United Arab Emirates, where it is being evaluated as a monotherapy and in combination with chemotherapy in RET fusion positive advanced NSCLC.
About Kelun-Biotech
Kelun-Biotech (6990.HK) is a holding subsidiary of Kelun Pharmaceutical, which focuses on the R&D, manufacturing, commercialization and global collaboration of innovative biological drugs and small molecule drugs. Kelun-Biotech focuses on major disease areas such as solid tumors, autoimmune, and metabolic diseases, and in establishing a globalized drug development and industrialization platform to address the unmet medical needs in China and the rest of world. Kelun-Biotech is committed to becoming a leading global enterprise in the field of innovative drugs. At present, Kelun-Biotech has more than 30 ongoing key innovative drug projects, of which 4 projects with 8 indications have been approved for marketing, 1 project is in the NDA stage and more than 10 projects are in the clinical stage. Kelun-Biotech has established one of the world's leading proprietary ADC and novel DC platforms, OptiDC™, and has 2 ADC projects with 5 indications approved for marketing, and multiple ADC and novel DC assets in clinical or preclinical research stage. For more information, please visit https://en.kelun-biotech.com/.
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
Kelun-Biotech Presents Pivotal Phase II Data for Lunbotinib Fumarate (A400/EP0031) in RET Fusion-Positive NSCLC at 2026 ASCO
Kelun-Biotech Presents Pivotal Phase II Data for Lunbotinib Fumarate (A400/EP0031) in RET Fusion-Positive NSCLC at 2026 ASCO
Kelun-Biotech Presents Pivotal Phase II Data for Lunbotinib Fumarate (A400/EP0031) in RET Fusion-Positive NSCLC at 2026 ASCO
Kelun-Biotech Presents Pivotal Phase II Data for Lunbotinib Fumarate (A400/EP0031) in RET Fusion-Positive NSCLC at 2026 ASCO
Kelun-Biotech Presents Pivotal Phase II Data for Lunbotinib Fumarate (A400/EP0031) in RET Fusion-Positive NSCLC at 2026 ASCO
Kelun-Biotech Presents Pivotal Phase II Data for Lunbotinib Fumarate (A400/EP0031) in RET Fusion-Positive NSCLC at 2026 ASCO
Kelun-Biotech Presents Pivotal Phase II Data for Lunbotinib Fumarate (A400/EP0031) in RET Fusion-Positive NSCLC at 2026 ASCO
